“…If characterization of the underlying mutation is desirable, we propose that, initially, genomic DNA and reticulocyte RNA should be compared for the reduced expression of one cDNA allele using the (AC) n repeat (Jarolim et al, 1995;Randon et al, 1997;Miraglia del Giudice et al, 1998b) and/or other ANK1 polymorphisms, and to proceed with SSCP screening of all ANK1 exons only in patients who show the absence of one ankyrin allele in the reticulocyte RNA. In families that do not show a reduced expression of one ankyrin cDNA allele, we recommend comparing genomic DNA and mRNA (as cDNA) for a reduced expression of one cDNA allele using frequent polymorphisms of other frequently affected genes in HS such as band 3 (Eber et al, 1996;Jarolim et al, 1992Jarolim et al, , 1997 or b-spectrin I (Hassoun et al, 1997;Dhermy et al, 1998;Miraglia del Giudice et al, 1998a). Exon 3, codon 61 (GTG fi GTC, silent) 267 G fi C 1( 0 AE02) 0 (0AE00) Exon 7, codon 218 (AAC fi AAA, Asn fi Lys) N218K 1 (0AE02) 1 (0AE01) Exon 36, codon 1455 (GTC fi GTT, silent) 4469 C fi T 1( 0 AE02) 0 (0AE00) Exon 36, codon 1462 (GCA fi GTA, Ala fi Val) A1462V 2 (0AE05) 1 (0AE03) Exon 38, codon 1658 (GAC fi GAT, silent) 5058 C fi T 1( 0 AE02) 1 (0AE01)…”